HIV/AIDS

BIT225 Phase I Clinical Trial Successfully Completed

Published in AIDS Weekly, September 3rd, 2007

The Directors of Biotron Limited ('Biotron') are pleased to advise that a Phase I clinical trial of BIT225, an orally dosed antiviral drug with the potential to treat both HIV and hepatitis C virus (HCV), has been successfully completed.

"The completion of this human trial is an important milestone in the development of BIT225", said Dr Michelle Miller, Managing Director, "We anticipate advancing the drug into Phase Ib/IIa clinical studies later this year." Protocols and regulatory applications for these new studies are being finalised.

The data from this Phase I clinical trial indicate BIT225 was well tolerated, with no dose limiting toxicities....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2007-09-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry